Compare Carnival Corp (CCL) vs TG Therapeutics Inc (TGTX) Price & Performance

Carnival Corporation (CCL) trades at $27.77, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, while net income turned positive at $2.76B. Technical indicators show bearish momentum despite neutral oscillators, with key support at $27 and resistance at $28. Recent corporate developments include new voyage bookings through 2029 and continued dividend payments of $0.15 per share.

CCL presents a compelling recovery story with improving profitability and debt reduction, though near-term technical weakness and fuel cost risks persist. Analyst consensus remains bullish with a $35.18 price target representing 27% upside potential. The stock offers exposure to the rebounding cruise industry but faces sensitivity to economic conditions and operational execution challenges.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.